Table 4.
Hemolytic activity of the tested peptides.
| Peptide | Alternate name | aHmax | bH50 (μM) | |
|---|---|---|---|---|
| (%) | Peptide Concentration (μM) | |||
| LfcinB (20–25) | Monomer | 7.1 | 25 | >100 |
| PLS | Palindromic | 24.8 | 100 | >100 |
| LfcinB (17–31) | Reference Peptide | 6.6 | 25 | >100 |
| LfcinB (20–25)2 | Dimeric | 5.6 | 100 | >100 |
| LfcinB (20–25)4 | Tetrameric | 49.1 | 100 | >100 |
a
Hmax.: Maximum hemolytic activity attained of human red blood cells after 2 h of treatment at 37°C with each peptide molecule.
Peptide concentration: concentration (μM) of peptide corresponding to Hma.
b
H50: concentration of peptide (μM) leading to 50% hemolysis of human red blood cells after 2 h of treatment at 37°C.